Form 4: Vaxcyte CFO Andrew Guggenhime Executes Option and Sells Shares
SEC Form 4 Filing
Andrew Guggenhime, CFO of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged trading plan.
Summary
- On August 19, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., exercised options to purchase 8,000 shares of common stock at a price of $5.35 per share.
- He then sold 4,994 shares at a weighted average price of $78.248, with prices ranging from $77.875 to $78.78.
- Additionally, he sold 3,006 shares at a weighted average price of $79.135, with prices ranging from $78.88 to $79.66.
- Following these transactions, Guggenhime directly owns 96,720 shares of Vaxcyte common stock and 328,827 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the executive's confidence in the company.
Industry Context
Insider transactions are common and closely monitored, especially in biotech companies like Vaxcyte, as they can provide insights into management's perspective on the company's prospects. The use of a pre-arranged trading plan (Rule 10b5-1) suggests the transactions were planned in advance and not based on immediate inside information.
Comparison to Industry Standards
- Comparing Vaxcyte's insider trading activity to companies like Moderna (MRNA) or BioNTech (BNTX) shows similar patterns of executives exercising options and selling shares.
- The trading activity is typical for executives holding significant equity compensation.
- The use of a 10b5-1 plan is a common practice to avoid accusations of trading on inside information, similar to plans used by executives at Regeneron (REGN) and Gilead Sciences (GILD).
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- However, the pre-planned nature of the sales mitigates concerns about insider information being used.
Key Dates
| Date | Description |
|---|---|
| 05/01/2021 | 1/4 of the shares subject to the option vested |
| 06/30/2023 | Rule 10b5-1 trading plan adopted |
| 08/19/2024 | Earliest transaction date: Exercise of stock options and sale of shares |
| 08/20/2024 | Date of Form 4 signature |
| 05/11/2030 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.